Anscheinend verwenden Sie einen älteren Internet Explorer. Leider unterstützen wir, genau wie Microsoft, diesen Browser nicht mehr. Sie werden also Fehlermeldungen und ein inkonsistentes Design erleben.
Bitte haben Sie Verständnis und entschuldigen Sie die Unannehmlichkeiten.
toggle menu

Tubulis – a future ADC leader on a rapid development path accepted in German

Accelerator Life Sciences programTubulis aims to develop a new generation of antibody-drug conjugates (ADCs). By using a dual platform approach, the company is able to create uniquely matched ADCs that are tailored to each indication and can make a difference for cancer patients and beyond.

Over the past year, the company has made tremendous progress in its corporate growth and pipeline development and is getting closer to entering clinical testing with its lead candidate, Tub-010, for the treatment of lymphoma. After making a strong public debut with a Series A financing round of EUR 10.7 million in 2020, the company has been working on expanding the team to accelerate its corporate growth and pipeline development. In April 2021, industry leader Dr. Günter Fingerle-Rowson joined the team as Chief Medical Officer. His proven track record of advancing product candidates into clinical use, will further accelerate Tubulis’ clinical development. In addition, Tubulis announced the formation of its newly established supervisory Board and welcomed the experienced biotech executive and company founder Dr. Christian Grøndahl, as Chairman of the Board.

Most recently, Tubulis has also been accepted into the German Accelerator Life Sciences program, which supports German high-potential growth companies in successfully entering the U.S. market and gaining recognition for their scientific approach.

German Accelerator empowers German start-ups to scale globally. It takes high-potential companies on a fast-paced learning journey to understand, discover, and access the world’s leading innovation hubs in the U.S. and Asia. Through highly customized programs, mentoring from experts as well as access to a vast network of business partners and investors, the program helps start-ups from all stages and across various industries on their way to international success, including an industry-focused Life Sciences program. Our programs are 100 percent free with the exception of our market discovery program. German Accelerator is run by German Entrepreneurship GmbH and is proudly financed by the German Federal Ministry for Economic Affairs and Energy (BMWi).